SCHEMBL64512

SCHEMBL64512

CC(=O)Nc1cc(C(=O)NC23CCC(CC2)Cn2c3nc(C(=O)NCc3ccc(F)cc3)c(O)c2=O)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.44
CYP2C9 P11712 1/20 0.41
ACHE P22303 2/20 0.40
GSK3B P49841 2/20 0.40
CALCA P06881 1/20 0.36
KCNE1 P15382 1/20 0.36
CCR1 P32246 1/20 0.36
KCNQ1 P51787 1/20 0.36
TP53 P04637 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
HTR1F P30939 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ERCC1 P07992 1/20 0.34
FEN1 P39748 1/20 0.34
ERCC4 Q92889 1/20 0.34
BLM P54132 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL64238 0.91 KCNH2 (0.44) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL52520 0.87 L3MBTL1 (0.47) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL63862 0.86 KCNH2 (0.43) KCNH2CYP2C9ACHEGSK3BKCNE1
SCHEMBL52470 0.86 KCNH2 (0.49) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL64509 0.85 EPHX2 (0.43) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL52562 0.84 KCNH2 (0.45) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL63488 0.84 KCNH2 (0.41) KCNH2CYP2C9CALCATP53NAMPT
SCHEMBL64481 0.84 KCNH2 (0.45) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL52473 0.83 KCNH2 (0.43) KCNH2CYP2C9CALCASMN1; SMN2ERCC1
SCHEMBL62729 0.83 KCNH2 (0.42) KCNH2CYP2C9CALCAKCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885ACHE 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.